Cabotegravir (Apretude)

All References

• Andrews CD, Bernard LS, Poon AY, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017;31:461-467.
  [PubMed Abstract]
• Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Curr Opin HIV AIDS. 2015;10:258-63.
  [PubMed Abstract]
• Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14:36.
  [PubMed Abstract]
• Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779–89.
  [PubMed Abstract]
• Ford SL, Lou Y, Lewis N, et al. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. Antivir Ther. 2019;24:301-8.
  [PubMed Abstract]
• Ford SL, Sutton K, Lou Y, et al. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Antimicrob Agents Chemother. 2017;61:e00487-17.
  [PubMed Abstract]
• Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12). pii: e01695-17.
  [PubMed Abstract]
• Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
  [PubMed Abstract]
• Landovitz RJ, Li S, Eron JJ Jr, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7:e472-e481.
  [PubMed Abstract]
• Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
  [PubMed Abstract]
• Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70:319-22.
  [PubMed Abstract]
• Lou Y, Buchanan AM, Chen S, et al. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects. Clin Pharmacol Drug Dev. 2016;5:509-516.
  [PubMed Abstract]
• Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e340.
  [PubMed Abstract]
• McCormack S, Boffito M. Long-acting cabotegravir for prevention: hope versus reality. Lancet HIV. 2017;4:e322-e323.
  [PubMed Abstract]
• Meyers K, Rodriguez K, Brill AL, et al. Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. AIDS Behav. 2018;22:1209-1216.
  [PubMed Abstract]
• Murray MI, Markowitz M, Frank I, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018;19:129-138.
  [PubMed Abstract]
• Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7:270ra5.
  [PubMed Abstract]
• Radzio-Basu J, Council O, Cong ME, et al. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nat Commun. 2019;10:2005.
  [PubMed Abstract]
• Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46:445-56.
  [PubMed Abstract]
• Rusconi S, Marcotullio S, Cingolani A. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective. New Microbiol. 2017;40:75-79.
  [PubMed Abstract]
• Soudeyns H, Dumond J. Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir. AIDS. 2020;34:2137-2139.
  [PubMed Abstract]
• Trezza C, Ford SL, Gould E, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83:1499-1505.
  [PubMed Abstract]
• Trezza C, Ford SL, Gould E, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83:1499-1505.
  [PubMed Abstract]
• Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS (Auckl). 2016;8:157-164.
  [PubMed Abstract]
• Zhou T, Su H, Dash P, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018;151:53-65.
  [PubMed Abstract]